Insights into how Novo Nordisk's Saxenda cuts food cravings may inspire new obesity drugs

Scientists at the University of Pennsylvania have shed light on how the popular GLP-1 obesity drug liraglutide interacts with a set of neurons in the brain to exert its appetite-suppressing effect, a finding they say could inspire more effective treatments for obesity.